The UK synthetic biology company Evonetix Ltd has raised $30 million in a Series B financing round led by Foresite Capital, a San Francisco, US-based venture capital company. Evonetix will use the proceeds for the development of technology enabling the synthesis of DNA on a chip. The silicon chip, which is made by a process technology known as MEMS, integrates physics with biology, and controls the synthesis of DNA at many thousands of independently controlled reaction sites or pixels on the chip surface.
